Accessibility Menu
Armata Pharmaceuticals logo

Armata Pharmaceuticals(NYSEMKT) ARMP

Market Cap$199.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)+15%
5 Year+42%
1 Year+110%
1 Month+18%
$5.28
-2.86%
-0.16Today
After hours$5.32+$0.04 (+0.85%)
Armata Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 5.372026-08-28
Armata Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.29%USD 5.102026-08-21
1 month+17.51%USD 4.572026-07-29
3 month-34.27%USD 8.172026-05-29
Year to date-14.49%USD 6.282025-12-31
1 year+109.77%USD 2.562025-08-28
3 year+72.12%USD 3.122023-08-29
5 year+41.69%USD 3.792021-08-27
Since inception+15.48%USD 4.652019-05-10

Armata Pharmaceuticals Financials at a Glance

Market Cap

$199.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$3.30M

Net Income (TTM)

-$192.18M

EPS (TTM)

-$7.59

P/E Ratio

-0.71

Dividend

$0.00

Beta (Volatility)

0.42 (Low)

Price

$5.28

Volume

49,709.275

Open

$5.37

Previous Close

$5.37

Daily Range

$4.99 - $5.45

52-Week Range

$2.40 - $16.34

Estimated Earnings Date

Nov 11, 2026

ARMP News

Foolcom-Featured.png

Armata Posts 59 Percent Q2 Revenue Jump

Motley Fool Markets TeamAug 12, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Armata Pharmaceuticals

Armata makes special viruses that kill harmful bacteria. These treatments help patients with infections that resist normal antibiotics. The company aims to fight superbugs while keeping healthy bacteria safe.

The Search for New Cures

  • AP-SA02: An injectable treatment for serious blood infections caused by Staphylococcus aureus bacteria.
  • AP-PA02: A mist-based therapy for chronic lung infections in patients with cystic fibrosis or other respiratory diseases.
  • AP-PA03: A candidate currently being tested to treat severe pneumonia in hospitalized patients.
  • Synthetic Phage Candidates: Modified virus treatments developed through a partnership with Merck & Co. for various infectious diseases.

Strategic Deals and Big Awards

  • On January 23, 2026, Armata extended its credit agreements with Innoviva Strategic Opportunities LLC through June 2027.
  • In December 2025, the company launched a stock sale program with JonesTrading Institutional Services LLC to raise up to $100 million.
  • Armata secured $4.65 million in extra funding from the Medical Technology Enterprise Consortium in April 2025.
  • In August 2025, it signed a $15 million loan agreement with Innoviva Strategic Opportunities LLC to fund operations.

Why Their Science Stands Out

Armata runs its own manufacturing facility in Los Angeles to produce high-purity clinical materials. This setup lets the company control the entire process from discovery to final production using current Good Manufacturing Practices (cGMP).

A Look at the Numbers

  • Revenue reached $1.1 million in Q4 2025, down 12.1% from the previous year.
  • Operating loss was $8.4 million in Q4 2025, improved 20.2% from a $10.5 million loss in Q4 2024.
  • Net loss reached $124.3 million in Q4 2025, worsening from a $2.6 million profit in Q4 2024.
  • Operating cash flow was negative $6.7 million in Q4 2025, improved 15.8% year-over-year.

Evolution of the Business

Armata has transitioned from early research to late-stage clinical testing of virus-based medicines for drug-resistant infections. It maintains internal manufacturing while securing large investments from strategic partners and government grants.

AI Generated • May 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

61

CEO

Deborah L. Birx, MD

Website

www.armatapharma.com

Headquarters

Los Angeles, CA 90066, US

ARMP Financials

Key Financial Metrics (TTM)

Gross Margin

68.23%

Operating Margin

-1233.59%

Net Income Margin

-5825.34%

Return on Equity

89.70%

Return on Capital

-44.97%

Return on Assets

-213.65%

Earnings Yield

-1.41%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$199.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

37.18M

Volume

49.71K

Avg. Volume

151.49K

Financials (TTM)

Gross Profit

$2.25M

Operating Income

-$40.70M

EBITDA

-$168.97M

Operating Cash Flow

-$25.42M

Capital Expenditure

-$374.00K

Free Cash Flow

-$25.79M

Cash & ST Invst.

$23.95M

Total Debt

$313.95M

Armata Pharmaceuticals Performance Analysis

Armata Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 5,508,00023.1%
20232023-12-31USD 4,529,000-17.8%
20242024-12-31USD 5,174,00014.2%
20252025-12-31USD 4,904,000-5.2%
Armata Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-100.0%
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30218.1%
Armata Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.0812.1%
20232023-12-31USD -1.9177.8%
20242024-12-31USD -0.52-72.7%
20252025-12-31USD -4.80816.8%
Armata Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-64.4%
Q42025-12-31-362.2%
Q12026-03-317.6%
Q22026-06-3091.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$2.51M

+15.7%

Gross Profit

$1.92M

+6.4%

Gross Margin

76.45%

N/A

Market Cap

$199.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.27M

N/A

Employees

61

N/A

Net Income

$74.14M

+555.0%

EBITDA

$81.37M

+771.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$23.95M

+453.4%

Total Debt

$313.95M

+118.1%

Accounts Receivable

$2.53M

+16.8%

Inventory

$0.00

N/A

Long Term Debt

$67.85M

+150.1%

Short Term Debt

$246.11M

+110.7%

Return on Assets

-2.14%

N/A

Return on Invested Capital

25.40%

N/A

Free Cash Flow

-$8.68M

-18.0%

Operating Cash Flow

-$8.67M

-20.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IPHAInnate Pharma S.A.
$2.22-0.45%
CDXSCodexis, Inc.
$1.59-4.22%
IMDXInsight Molecular Diagnostics Inc.
$4.13-3.73%
NTHINeonc Technologies Holdings, Inc.
$4.69+1.85%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$217.55-0.05%
PCGPG&E
$16.60-0.08%
BITOProShares Trust - ProShares Bitcoin ETF
$10.45-0.03%
IRENIren
$35.45-0.13%

Questions About ARMP

What is the current price of Armata Pharmaceuticals?

Armata Pharmaceuticals is trading at $5.37 per share.

What is the 52-week range for Armata Pharmaceuticals?

Over the past 52 weeks, Armata Pharmaceuticals has traded between $2.40 and $16.34.

How much debt does Armata Pharmaceuticals have?

As of the most recent reporting period, Armata Pharmaceuticals reported total debt of $313.95M.

How much cash does Armata Pharmaceuticals have on hand?

Armata Pharmaceuticals reported $23.95M in cash and cash equivalents in its most recent financial results.

What is Armata Pharmaceuticals’s dividend yield?

Armata Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services